This article needs additional citations for verification. (March 2021) |
Clinical data | |
---|---|
Pronunciation | /ˌpɛnˈsaɪkloʊˌvɪər/[1] |
Trade names | Denavir |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697027 |
Pregnancy category |
|
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 1.5% (oral), negligible (topical) |
Protein binding | <20% |
Metabolism | Viral thymidine kinase |
Elimination half-life | 2.2–2.3 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.189.687 |
Chemical and physical data | |
Formula | C10H15N5O3 |
Molar mass | 253.262 g·mol−1 |
3D model (JSmol) | |
Melting point | 275 to 277 °C (527 to 531 °F) |
| |
| |
(verify) |
Penciclovir is a guanosine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. Because penciclovir is absorbed poorly when given orally (by mouth) it is more often used as a topical treatment. It is the active ingredient in the cold sore medications Denavir (NDC 0135-0315-52), Vectavir and Fenivir. Famciclovir is a prodrug of penciclovir with improved oral bioavailability.
Penciclovir was approved for medical use in 1996.[2]